DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 5:21 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 1 added · 12 modified; 8 with only figures updated

  1. Modified · Critical Accounting Estimates

    Overview of Financial Results The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow. Key Highlights for the Three Months Ended March 31June 30, 2026 include the following: Revenue | Gross Profit | Operating Income | Net Income | Operating Cash Flow $1.191.31 billion | $750.3830.0 million | $255.3318.3 million | $199.5249.1 million | $525.6269.2 million up 1513% from the same period in 2025 | up 2720% from the same period in 2025 | up 9150% from the same period in 2025 | up 8939% from the same period in 2025 | up 186down 11% from the same period in 2025

12 more changes in this Item, word by word, in Powerpack.

Powerpack